Qiqi Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Qiqi Wang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chongshan Dai
State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
1 shared publication - Haiyang Jiang
State Key Laboratory of Veterinary Public Health and Safety, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
1 shared publication - Jiankang Ren
State Key Laboratory of Veterinary Public Health and Safety, Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, China Agricultural University, Beijing 100193, China
1 shared publication - Jianzhong Shen
State Key Laboratory of Veterinary Public Health and Safety, College of Veterinary Medicine, China Agricultural University
1 shared publication - Tony Velkov
Department of Pharmacology, Monash Biomedicine Discovery Institute, Monash University
1 shared publication - Yunpeng Yi
Shandong Provincial Key Laboratory of Livestock and Poultry Breeding, Institute of Poultry Science, Shandong Academy of Agricultural Science
1 shared publication
Latest Publications
- Open Access
- 15 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10037
Progress of AI-Driven Drug–Target Interaction Prediction and Lead Optimization
In modern pharmaceutical research and development (R&D), drug discovery remains a challenging process. Artificial intelligence (AI) has been extensively incorporated into various phases of drug discovery and development. AI enable effectively extract molecular structural features, perform in-depth analysis of drug–target interactions, and systematically model the relationships among drugs, targets, and diseases. These approaches improve prediction accuracy, accelerate discovery timelines, reduce costs from trial and error methods, and enhance success probabilities. This review summarizes recent advances in AI applications for drug design, including target identification, synthetic accessibility prediction, lead optimization, and ADMET property evaluation. Furthermore, it introduces various deep learning tools to guide researchers in selecting and implementing the most appropriate AI-driven strategies throughout the drug discovery process. We hope it can establish a conceptual framework intended to advance AI-driven methodologies in pharmaceutical research by comprehensively organizing novel perspectives and critical insights.
- 15 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 10037
Open AccessProgress of AI-Driven Drug–Target Interaction Prediction and Lead Optimization
In modern pharmaceutical research and development (R&D), drug discovery remains a challenging process. Artificial intelligence (AI) has been extensively incorporated into various phases of drug discovery and development. AI enable effectively extract molecular structural features, perform in-depth analysis of drug–target interactions, and systematically model the relationships among drugs, targets, and diseases. These approaches improve prediction accuracy, accelerate discovery timelines, reduce costs from trial and error methods, and enhance success probabilities. This review summarizes recent advances in AI applications for drug design, including target identification, synthetic accessibility prediction, lead optimization, and ADMET property evaluation. Furthermore, it introduces various deep learning tools to guide researchers in selecting and implementing the most appropriate AI-driven strategies throughout the drug discovery process. We hope it can establish a conceptual framework intended to advance AI-driven methodologies in pharmaceutical research by comprehensively organizing novel perspectives and critical insights.